Cargando…

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer

Over the last few decades, improved and more individualized treatment has contributed to the increased survival rate of patients with breast cancer. However, certain patients may receive excessive treatment resulting in undesired side effects. In a previous study, it was demonstrated that systemical...

Descripción completa

Detalles Bibliográficos
Autores principales: Fohlin, Helena, Bekkhus, Tove, Sandström, Josefine, Fornander, Tommy, Nordenskjöld, Bo, Carstensen, John, Stål, Olle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087479/
https://www.ncbi.nlm.nih.gov/pubmed/32257197
http://dx.doi.org/10.3892/mco.2020.2014
_version_ 1783509338363527168
author Fohlin, Helena
Bekkhus, Tove
Sandström, Josefine
Fornander, Tommy
Nordenskjöld, Bo
Carstensen, John
Stål, Olle
author_facet Fohlin, Helena
Bekkhus, Tove
Sandström, Josefine
Fornander, Tommy
Nordenskjöld, Bo
Carstensen, John
Stål, Olle
author_sort Fohlin, Helena
collection PubMed
description Over the last few decades, improved and more individualized treatment has contributed to the increased survival rate of patients with breast cancer. However, certain patients may receive excessive treatment resulting in undesired side effects. In a previous study, it was demonstrated that systemically untreated patients with estrogen receptor (ER)-positive/progesterone receptor (PR)-negative tumors with high Ras-related protein Rab-6C (RAB6C) expression levels (RAB6C(+)) had prolonged distant recurrence-free survival compared with that of patients exhibiting low RAB6C (RAB6C(-))-expressing tumors. The aim of the present study was to investigate whether RAB6C predicts the effectiveness of tamoxifen treatment. The present study used a dataset comprising 486 female patients with ER(+) tumors from a randomized study conducted by the Stockholm Breast Cancer Study Group between November 1976 and August 1990. The patients were considered as low-risk if their tumor size was ≤30 mm and their lymph node status was negative. Patients were followed up until distant recurrence, mortality or when 25 years after randomization was achieved, whichever occurred first. For patients with ER(+)/PR(-)/RAB6C(+) tumors, prolonged distant recurrence-free survival could not be observed if the patients were treated with tamoxifen [hazard ratio (HR), 1.82; 95% confidence interval (CI), 0.69-4.79; P=0.23], whereas patients with ER(+)/PR(-)/RAB6C(-) tumors had 75% reduced distant recurrence risk (HR, 0.25; 95% CI, 0.09-0.70; P=0.008). In the ER(+)/PR(+) subgroup, patients with RAB6C(-) and RAB6C(+) tumors benefited from tamoxifen treatment, though it was most evident in the RAB6C(+) group (HR, 0.27; 95% CI, 0.13-0.58; P=0.001). The results of the present study indicated that, for patients with ER(+)/PR(-) tumors, those with low RAB6C expression benefited from tamoxifen treatment, whereas no benefit was observed in patients with high RAB6C levels.
format Online
Article
Text
id pubmed-7087479
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-70874792020-04-02 Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer Fohlin, Helena Bekkhus, Tove Sandström, Josefine Fornander, Tommy Nordenskjöld, Bo Carstensen, John Stål, Olle Mol Clin Oncol Articles Over the last few decades, improved and more individualized treatment has contributed to the increased survival rate of patients with breast cancer. However, certain patients may receive excessive treatment resulting in undesired side effects. In a previous study, it was demonstrated that systemically untreated patients with estrogen receptor (ER)-positive/progesterone receptor (PR)-negative tumors with high Ras-related protein Rab-6C (RAB6C) expression levels (RAB6C(+)) had prolonged distant recurrence-free survival compared with that of patients exhibiting low RAB6C (RAB6C(-))-expressing tumors. The aim of the present study was to investigate whether RAB6C predicts the effectiveness of tamoxifen treatment. The present study used a dataset comprising 486 female patients with ER(+) tumors from a randomized study conducted by the Stockholm Breast Cancer Study Group between November 1976 and August 1990. The patients were considered as low-risk if their tumor size was ≤30 mm and their lymph node status was negative. Patients were followed up until distant recurrence, mortality or when 25 years after randomization was achieved, whichever occurred first. For patients with ER(+)/PR(-)/RAB6C(+) tumors, prolonged distant recurrence-free survival could not be observed if the patients were treated with tamoxifen [hazard ratio (HR), 1.82; 95% confidence interval (CI), 0.69-4.79; P=0.23], whereas patients with ER(+)/PR(-)/RAB6C(-) tumors had 75% reduced distant recurrence risk (HR, 0.25; 95% CI, 0.09-0.70; P=0.008). In the ER(+)/PR(+) subgroup, patients with RAB6C(-) and RAB6C(+) tumors benefited from tamoxifen treatment, though it was most evident in the RAB6C(+) group (HR, 0.27; 95% CI, 0.13-0.58; P=0.001). The results of the present study indicated that, for patients with ER(+)/PR(-) tumors, those with low RAB6C expression benefited from tamoxifen treatment, whereas no benefit was observed in patients with high RAB6C levels. D.A. Spandidos 2020-05 2020-03-09 /pmc/articles/PMC7087479/ /pubmed/32257197 http://dx.doi.org/10.3892/mco.2020.2014 Text en Copyright: © Fohlin et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Fohlin, Helena
Bekkhus, Tove
Sandström, Josefine
Fornander, Tommy
Nordenskjöld, Bo
Carstensen, John
Stål, Olle
Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer
title Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer
title_full Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer
title_fullStr Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer
title_full_unstemmed Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer
title_short Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer
title_sort low rab6c expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087479/
https://www.ncbi.nlm.nih.gov/pubmed/32257197
http://dx.doi.org/10.3892/mco.2020.2014
work_keys_str_mv AT fohlinhelena lowrab6cexpressionisapredictoroftamoxifenbenefitinestrogenreceptorpositiveprogesteronereceptornegativebreastcancer
AT bekkhustove lowrab6cexpressionisapredictoroftamoxifenbenefitinestrogenreceptorpositiveprogesteronereceptornegativebreastcancer
AT sandstromjosefine lowrab6cexpressionisapredictoroftamoxifenbenefitinestrogenreceptorpositiveprogesteronereceptornegativebreastcancer
AT fornandertommy lowrab6cexpressionisapredictoroftamoxifenbenefitinestrogenreceptorpositiveprogesteronereceptornegativebreastcancer
AT nordenskjoldbo lowrab6cexpressionisapredictoroftamoxifenbenefitinestrogenreceptorpositiveprogesteronereceptornegativebreastcancer
AT carstensenjohn lowrab6cexpressionisapredictoroftamoxifenbenefitinestrogenreceptorpositiveprogesteronereceptornegativebreastcancer
AT stalolle lowrab6cexpressionisapredictoroftamoxifenbenefitinestrogenreceptorpositiveprogesteronereceptornegativebreastcancer